Reuters  Aug 23  Comment 
Laboratory Corporation Of America Holdings :
newratings.com  Aug 9  Comment 
WASHINGTON (dpa-AFX) - Laboratory Corp. of America Holdings (LH) said it has commenced its cash tender offer for all outstanding shares of the common stock of Sequenom, Inc. (SQNM) for $2.40 per share. The tender offer is being made by Savoy...
Benzinga  Jul 28  Comment 
The following are the M&A deals, rumors and chatter circulating on Wall Street for Wednesday July 27, 2016:   Sequenom Being Acquired by Lab Corp for $2.40/Share in Cash The Deal: Laboratory Corporation of America Holdings (NYSE:...
newratings.com  Jul 27  Comment 
WASHINGTON (dpa-AFX) - Laboratory Corporation of America Holdings (LH) announced, for fiscal 2016, the company expects adjusted EPS of $8.60 to $8.95, versus prior guidance of $8.55 to $8.95. Analysts polled by Thomson Reuters expect the company...
Reuters  Jul 27  Comment 
Laboratory Corporation of America Holdings said it would buy Sequenom Inc, a maker of non-invasive prenatal tests for reproductive health, for about $371 million, including debt.
MarketWatch  Jul 27  Comment 
Sequenom Inc.'s stock nearly tripled in premarket trade Wednesday, after the patient management information company said it agreed to be bought by Laboratory Corp. of America Holdings in deal valued at $302 million, or $371 million including...
newratings.com  Jul 7  Comment 
WASHINGTON (dpa-AFX) - Sequenom Inc. (SQNM) announced a significant performance enhancement to the MaterniT GENOME laboratory-developed test and will present new data at the 20th International Conference on Prenatal Diagnosis and Therapy, July...
Clusterstock  Jun 23  Comment 
By Andrew Chung NEW YORK (Reuters) - Companies, trade groups and universities who fear that many important discoveries may no longer qualify for patents are among a broad coalition urging the U.S. Supreme Court to review the cancellation of a...


Sequenom, Inc. (NYSE:SQNM)'s flagship product is the MassARRAY genetic analysis system, used to identify and describe the genetic mutations involved in diseases such as Down's Syndrome and cancer. When combined with all of its complementary software, chips, and reagents, the MassARRAY system accounts for all of Sequenom's revenue. The MassARRAY system has been sold globally since 2000 and while revenue growth from the system has been strong in the past three years, it holds only 7% of the genetic analysis market and competes with Illumina (ILMN) , Applera (ABI), and Affymetrix (AFFX)[1][2].

Most of Sequenom's revenues come from the systems that it sells and most of its costs also arise from the production of these machines. Sequenom and its competitors make most of their profit from selling complementary products to these systems, such as single-use reagents, software, and complementary hardware after customers commit to their genetic analysis system[3]. This makes market share particularly important.

Corporate Overview


Sequenom was founded in 1994 by Dr. Hubert Köster, who developed the core technology around which the company's major product, MassARRAY, is based. Sequenom held its IPO in 2000, after the launch of its MassARRAY system into the genetic research market[4].

Business & Financial Metrics[5]

In 2009, SQNM incurred a net loss of $71.0 million on revenues of $37.9 million. This represents a 60.8% increase in net loss and a 19.7% decrease in total revenues from 2008, when the company lost $44.2 million on $47.1 million in revenues.

Business Segments[6]

SQNM operates in two reportable business segments.

  • Genetic Analysis (99.8% of revenue): This segment sells MassARRAY, the company's neucleic acid analysis platform - the MassARRAY system can identify information about genes and DNA in target cells.[7]
  • Molecular Diagnostics (0.2% of revenue): This segment is researching noninvasive molecular diagnostic tests for detecting prenatal genetic disorders and diseases, women's health issues, cancer cells, and other medical problems. This segment was established more recently than the Genetic Analysis segment and has not reached profitability.[6]

Trends and Forces

MassARRAY is Expanding into the Emerging and High Potential Clinical Research Market

The customers of MassARRAY largely lie in the research market, which is focused on making initial genetic discoveries. However, the clinical analysis market, which is concerned with establishing the use of genetic information for the benefit of the general population, has potential to be significantly larger, is less price competitive, and allows lower throughput but demands high accuracy and consistency. Sequenom believes that the relatively high sensitivity, specificity, and reproducibility of MassARRAY provides an opportunity to be competitive in the clinical analysis segment[8]. However, clinical genetic research is still an emerging market. The ability of Sequenom to penetrate into the clinical research market will be critical for it to grab market share from its competitors, which include Illumina, Applied Biosystems, and Affymetrix.

The Success of Sequenom's Entrance into Prenatal Diagnostics

Sequenom has little prior experience in diagnostics, but has secured exclusive rights for testing fetal genetic material from maternal blood[9]. Furthermore, in June 2008, Sequenom announced clinical results for its SEQureDxTM-based test for Down syndrome showed 100% sensitivity and specificity for detecting the genetic abnormality in prenatal screening[10]. In the United States, where there are over 6 million pregnancies per year, the market for prenatal screening tests like Sequenom's is upward of $2 billion[11].

Despite the promise of this market opportunity for Sequenom, there are many hurdles that must be crossed before such revenues are realized. First, in order to market prenatal screening tests in the United States, Sequenom is required to validate the effectiveness of the screen through the Food and Drug Administration (FDA). While Sequenom may sell the reagents involved in the test to CLIA-certified labs without FDA approval, in order to directly market its diagnostic kit to physicians as a screening tool, the FDA must approve it, either through a 510K process or premarket approval (PMA) application. The 510K validation process can take three to six months, while building a full PMA can take over a year[12]. Sequenom's relative inexperience in FDA regulation means that it will be important to keep an eye on these diagnostics as they are developed and validated by the FDA.

The Rise of Personalized Medicine in Health Care

Pharmacogenomics is the study of how genetic codes, or markers, in the DNA of a patient correspond to the efficacy and toxicity of potential therapeutics. Personalized medicine is the use of pharmacogenomics to guide prescription, and even development of such therapeutics. Analysts predict that personalized medicine will become a part of mainstream practice in medical care within 10 years. [13].

As personalized medicine becomes a standard practice in the medical community, physicians will need genetic analyzers, such as those that Sequenom develops, to make prescribing decisions. In addition, the development of new drugs for the personalized medicine era that are targeted at patients with specific genetic profiles will require companion tests powered by technologies such as Sequenom's iPlex system (see Herceptin and the companion HercepTest as an example).

The Threat of Competition from Home Brew Diagnostic Tests

Many genetic tests now fall into the "home brew" category of tests that are developed within medical labs in which they are used. Home brew tests are not regulated by the FDA, so as long as the lab has scientists skilled enough to create the tests, there is a relatively low barrier to entry for these tests to compete with Sequenom's prenatal screening tests[14].

However, malpractice suits arising from parents of children born with genetic abnormalities are common in cases where the parents can show that the genetic test was inappropriately used or interpreted. This malpractice liability provides an incentive to adopt a standard of care practice that is both effective and well regulated[15]. Sequenom's tests are required to be strongly validated and regulated in order to attain FDA approval, which will ease some of the burden of malpractice liability on physicians using the test.

The Continuance of Government Interest in Genetic Analysis

The relationship of government interest to Sequenom's success is twofold. First, Sequenom's MassARRAY system has been used for livestock DNA testing since 1999, which is a market created by government mandate to track and verify the age and origin of livestock commodities. Second, Sequenom systems are directly involved in or benefit from government sponsored initiatives such as Cancer Genome Atlas (TCGA) and the HapMap initiative. Currently the TCGA is backed by over $100 million in funds from the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), and will advance the use of genetic diagnostics. The HapMap project is an international project to characterize the genomes of populations across the world, and uses the MassARRAY for its studies. Government funding of projects such as these are connected with Sequenom's success.


MassARRAY competes with Illumina (ILMN), Applied Biosystems, and Affymetrix (AFFX) in the SNP Genotyping market.

Sequenom's entry into the multi-billion dollar molecular diagnostics market is specific to prenatal screening tests in which the major competition is with in-house labs at hospitals that make their own home brew tests. The other main sources of competition in this realm come from alternative prenatal screening techniques such as DNA extracted from maternal urine or cervical swab samples rather than serum[16].


  1. Sequenom (SQNM) Form 10-K, Fiscal year 1999, p. 41
  2. Kalorama Information. SNP Genotyping and Analysis Markets. June 2008, p. 166
  3. Sequenom (SQNM) Form 10-K, Fiscal year 2007, p. 32
  4. Sequenom (SQNM) Form 10-K, Fiscal year 1999, p. 27
  5. SQNM 2009 10-K pg. 43  
  6. 6.0 6.1 SQNM 2009 10-K pg. 2  
  7. SQNM 2009 10-K pg. 6  
  8. Sequenom (SQNM) Form 10-K, Fiscal year 2007, p. 33
  9. Sequenom (SQNM) Form 10-K, Fiscal year 2007, p. 13
  10. Sequenom Announces Additional, Positive Results for Down Syndrome Test at Analyst Briefing, 2008.
  11. Marcial: Sequenom's Down Syndrome Test, Business Week, August 2008.
  12. Sequenom (SQNM) Form 10-K, Fiscal year 2007, p. 19
  13. [www.personalizedmedicinecoalition.org/objects/pdfs/PMC_Incentives_for_PM_2008_January.pdf Personalized Medicine: The Emerging Pharmacogenomics Revolution. PriceWaterhouseCoopers. Feb 2005.]
  14. Genetic Testing, Genome.gov
  15. Reproductive Genetic Testing: Issues and Options for Regulators. Genetics and Public Policy Center, 2004.
  16. Sequenom (SQNM) Form 10-K, Fiscal year 2007, p. 8
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki